Want to see SE:FLUI full AI Analyst Report?

Fluicell AB (FLUI) Price & Analysis

0 Followers

FLUI Stock Chart & Stats

kr10.00

>-kr0.01(-1.38%)

At close: Mar 06 4:00 PM EST

kr10.00

>-kr0.01(-1.38%)

Day’s Range― - ―

52-Week Rangekr7.65 - kr67.20

Previous CloseN/A

Volume175.18K

Average Volume (3M)16.23K

Market Cap

kr39.29M

Enterprise Valuekr13.95

Total Cash (Recent Filing)kr1.30M

Total Debt (Recent Filing)kr0.00

Price to Earnings (P/E)―

Beta1.13

Next Earnings

Aug 21, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.71

Shares Outstanding1,373,703

10 Day Avg. Volume8,193

30 Day Avg. Volume16,225

Financial Highlights & Ratios

PEG Ratio1.01

Price to Book (P/B)74.56

Price to Sales (P/S)135.42

P/FCF Ratio-59.71

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)kr68.60M

Bulls Say, Bears Say

Bulls Say

Revenue RecoveryThe sharp revenue recovery indicates improving commercial traction and customer demand for Fluicell’s platforms. Sustaining this momentum could strengthen operating leverage and broaden the company’s ability to serve research, drug discovery, and cell-based applications.

Debt-Free Balance SheetZero debt reduces refinancing pressure, interest obligations, and vulnerability to credit-market disruption. Positive equity provides a stronger financial base while Fluicell develops its products, although future funding may still be required before profitability.

Microfluidic Platform PotentialThe company operates in specialized single-cell and microfluidic workflows supporting drug discovery, disease modeling, and cell characterization. These applications can create durable demand as laboratories adopt more precise and data-rich research methods.

Bears Say

Persistent UnprofitabilityPersistent operating and net losses show that current revenue is not yet sufficient to support the cost base. Until margins improve materially, Fluicell may have limited ability to reinvest, absorb setbacks, or fund expansion from internally generated earnings.

Ongoing Cash BurnNegative operating and free cash flow indicate limited near-term self-financing capacity. Continued cash consumption can create recurring funding needs, potentially requiring equity issuance or other financing that could constrain strategic flexibility before the business reaches scale.

Unscaled Cost StructureVolatile annual results and a prior period of negative gross profit suggest the business has not yet established a consistently scalable operating model. This uncertainty makes future margins less predictable and increases execution risk as revenue expands.

FLUI FAQ

What was Fluicell AB’s price range in the past 12 months?

Fluicell AB lowest stock price was kr7.65 and its highest was kr67.20 in the past 12 months.

What is Fluicell AB’s market cap?

Fluicell AB’s market cap is kr39.29M.

When is Fluicell AB’s upcoming earnings report date?

Fluicell AB’s upcoming earnings report date is Aug 21, 2026 which is tomorrow.

How were Fluicell AB’s earnings last quarter?

Fluicell AB released its earnings results on May 08, 2026. The company reported kr2.409 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.

Is Fluicell AB overvalued?

According to Wall Street analysts Fluicell AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Fluicell AB pay dividends?

Fluicell AB does not currently pay dividends.

What is Fluicell AB’s EPS estimate?

Fluicell AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Fluicell AB have?

Fluicell AB has 1,373,703 shares outstanding.

What happened to Fluicell AB’s price movement after its last earnings report?

Fluicell AB reported an EPS of kr2.409 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 48.444%.

Which hedge fund is a major shareholder of Fluicell AB?

Currently, no hedge funds are holding shares in SE:FLUI

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Fluicell AB

Fluicell AB (publ) is a global provider of cutting-edge single-cell discovery platforms, catering to applications in biomedicine, drug development, and bioprinting. The company's product line includes the BioPen PRIME and BioPen FLEX microfluidic systems, engineered for precise localized solution delivery during single-cell experiments and for managing the chemical microenvironment of individual intact cells within tissue or cell cultures. Furthermore, Fluicell offers the Dynaflow Resolve system, a specialized platform for secondary ion channel screening that enables the measurement of various ion channel currents in a patch-clamp recording configuration. This Swedish company, headquartered in Gothenburg, was founded in 2012.